Zentalis Pharma

$72.70 0.00% ($0.00)

Get ready to invest

About Zentalis Pharma

Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.

Popular Stocks	Price	Change
DiDi Global Inc DIDI	$6.07 22.18%	22.18%
AMC Entertainment AMC	$29.01 4.19%	4.19%
Lucid Group LCID	$47.27 2.35%	2.35%
AT&T T	$23.46 1.78%	1.78%
Alibaba BABA	$111.96 8.23%	8.23%
Bank of America BAC	$43.87 2.27%	2.27%
Docusign DOCU	$135.09 42.22%	42.22%
Ford F	$19.14 3.67%	3.67%
Apple AAPL	$161.84 1.17%	1.17%
NIO NIO	$32.15 11.19%	11.19%